Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
866 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Not yet recruiting Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer
Condition: Bronchial Cancer
Intervention: Device: With and without SDB
3 Recruiting Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
Conditions: Carcinoma, Non-Small-Cell Lung;   Bronchial Neoplasms;   Carcinoma, Bronchogenic;   Lung Diseases;   Lung Neoplasms
Intervention:
4 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
5 Not yet recruiting International Lung Screen Trial (ILST)
Conditions: Non-small Cell Lung Cancer;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases;   Respiratory Tract Diseases;   Smokers at Risk of Lung Cancer
Intervention: Radiation: Low dose CT
6 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
Intervention:
7 Not yet recruiting Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Durvalumab;   Other: Durvalumab plus SBRT
8 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
9 Not yet recruiting A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Condition: NSCLC
Interventions: Drug: Fruquintinib;   Drug: Gefitinib
10 Not yet recruiting Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer
Condition: NSCLC
Interventions: Radiation: Conventional Fractionated Radiotherapy;   Radiation: Stereotactic Body Radiation Therapy
11 Not yet recruiting Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Condition: NSCLC
Intervention: Drug: Alflutinib
12 Recruiting Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
Condition: Extensive Stage Small Cell Lung Cancer
Intervention: Drug: temozolomide
13 Recruiting Study of ASN003 in Subjects With Advanced Solid Tumors
Conditions: Neoplasms;   Melanoma;   Colorectal Neoplasm;   Carcinoma, Non-small Cell Lung
Interventions: Drug: ASN003 ascending doses;   Drug: ASN003 MTD
14 Recruiting High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Icotinib
15 Recruiting Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Condition: Progression Free Survival
Interventions: Drug: Osimertinib;   Drug: docetaxel, bevacizumab
16 Recruiting Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Glesatinib;   Drug: Sitravatinib;   Drug: Mocetinostat;   Drug: Nivolumab
17 Not yet recruiting A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Conditions: Non-small Cell Lung Cancer;   Renal Cell Cancer;   Breast Cancer;   Bladder Cancer;   Head and Neck Cancer;   Colorectal Cancer
Intervention: Drug: SGN-2FF
18 Not yet recruiting Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Cisplatin;   Radiation: hypofractionated radiotherapy;   Drug: Pemetrexed;   Drug: Etoposide
19 Recruiting Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
Condition: Malignant Pleural Effusion
Intervention: Drug: Bevacizumab
20 Not yet recruiting Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
Condition: Non-small-cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: pemetrexed or gemcitabine plus carboplatin,;   Drug: bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.